Archive · 24 Jan 2026
Sun Pharma Approved for Generic Wegovy
Sun Pharma, a big Indian medicine company, got permission from the government to make and sell a generic version of a weight loss drug called Wegovy.
This drug, called Noveltreat, helps people manage their weight when they eat less and exercise more.
It will be available in different doses and comes in a pen for easy use.
Sun Pharma is the second company in India to get this permission.
The company's stock has been going down, but its competitor's stock went up a little.
Sun Pharma plans to launch the drug in March 2026 after the patent expires.
They also have another drug called Sematrinity for diabetes, which will be launched after the patent expires in December 2025.
Sun Pharma received DCGI approval for generic semaglutide (Noveltreat).
Noveltreat is for weight management and will be available in five dose strengths.
The drug will be launched in India after the semaglutide patent expires in March 2026.
Sun Pharma is the second Indian company to get approval for generic semaglutide.
Sun Pharma's stock has declined 7% in the past month, while Dr. Reddy’s stock is up 2% in early trade.
- Who
- Sun Pharmaceuticals Industries
- What
- Received DCGI approval for generic semaglutide (Noveltreat)
- When
- After Wegovy patent expiry in March 2026
- Where
- India
- Why
- To improve access to weight management drugs
Sun Pharma
Dr. Reddy’s Laboratories
Market Strategy
Sun Pharma
Sun Pharma plans to launch Noveltreat in March 2026 after the patent expiry and aims to improve access to generic semaglutide across India.
Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories aims to produce 12 million pens in the first year and has already started manufacturing and exporting generic semaglutide to non-patent markets.
- Company
- Sun Pharmaceuticals Industries
- Drug Name
- Noveltreat (generic semaglutide)
- Approval Authority
- Drug Controller General of India (DCGI)
- Patent Expiry
- March 2026
- Dose Strengths
- 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
- Competitor
- Dr. Reddy’s Laboratories
- Stock Performance (Sun Pharma)
- Down 7% in 1 month
- Stock Performance (Dr. Reddy’s)
- Down 3% in 1 month, up 2% in early trade
- Clinical Trial
- Phase III clinical trial conducted in India
- Market Opportunity
- Nearly one in four Indians aged 15–49 is overweight or obese, and over 101 million people in India have diabetes.
Sources
Sun Pharma gets DCGI approval for weight loss drug after Wegovy patent expiry
Sun Pharma gets nod to make generic Wegovy
Sun Pharma gets DCGI nod for generic semaglutide, plans India launch post patent expiry
